Novavax COVID-19 Vaccine Covovax Gets Emergency Use Nod In Thailand

Tiger Newspress2022-04-08

Novavax Shares Jumped 4% in Morning Trading.

Novavax COVID-19 vaccine Covovax gets emergency use nod in Thailand.

Novavax and Serum Institute of India (SII) said that the Thailand Food and Drug Administration granted emergency use authorization (EUA) to Novavax' protein-based COVID-19 vaccine NVX-CoV2373 for use in people 18 years of age and older.

The vaccine is made and marketed by SII under the brand name Covovax.

The companies said the approval was backed by data from clinical studies, including two phase 3 trials: PREVENT-19, which enrolled ~30K people aged 18 years and older in the U.S. and Mexico; and a trial with ~15K adult participants in the U.K.

The companies noted that Covovax has received emergency use listing from the World Health Organization, and EUA in India, Indonesia, The Philippines, and Bangladesh. The vaccine is also authorized for use in adolescents aged ≥12 to <18 years in India.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

WifeWhyWhy
2022-04-09
WifeWhyWhy
Ok
Joppee
2022-04-09
Joppee
keep on jabbing
LWayne
2022-04-09
LWayne
Still...
Blading23
2022-04-09
Blading23
Read
Will.I.AM
2022-04-09
Will.I.AM
Good news
TANJH
2022-04-09
TANJH
Ok

Leave a comment

513

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1114716222?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-04-08 22:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114716222","market":"us","top_or_hot":-1,"title":"Novavax COVID-19 Vaccine Covovax Gets Emergency Use Nod In Thailand","media":"Tiger Newspress","content":"<html><head></head><body><p>Novavax Shares Jumped 4% in Morning Trading.</p><p>Novavax COVID-19 vaccine Covovax gets emergency use nod in Thailand.</p><p><img src=\"https://static.tigerbbs.com/751bd25ab18229bbe96326cbcef41743\" tg-width=\"893\" tg-height=\"673\" width=\"100%\" height=\"auto\"/></p><p><a href=\"https://laohu8.com/S/NVAX\">Novavax </a> and Serum Institute of India (SII) said that the Thailand Food and Drug Administration granted emergency use authorization (EUA) to Novavax&#39; protein-based COVID-19 vaccine NVX-CoV2373 for use in people 18 years of age and older.</p><p>The vaccine is made and marketed by SII under the brand name Covovax.</p><p>The companies said the approval was backed by data from clinical studies, including two phase 3 trials: PREVENT-19, which enrolled ~30K people aged 18 years and older in the U.S. and Mexico; and a trial with ~15K adult participants in the U.K.</p><p>The companies noted that Covovax has received emergency use listing from the World Health Organization, and EUA in India, Indonesia, The Philippines, and Bangladesh. The vaccine is also authorized for use in adolescents aged ≥12 to &lt;18 years in India.</p><p></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax COVID-19 Vaccine Covovax Gets Emergency Use Nod In Thailand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax COVID-19 Vaccine Covovax Gets Emergency Use Nod In Thailand\n</h2>\n\n<h4 class=\"meta\">\n\n2022-04-08 22:41 北京时间&nbsp;&nbsp;&nbsp;<strong>Tiger Newspress</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax Shares Jumped 4% in Morning Trading.Novavax COVID-19 vaccine Covovax gets emergency use nod in Thailand.Novavax  and Serum Institute of India (SII) said that the Thailand Food and Drug ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVAX","symbol_name":"诺瓦瓦克斯医药","start_time":0,"source_url":"","article_id":"1114716222","we_media_id":"1079075236","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114716222","pubTimestamp":1649428908,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Tiger Newspress","introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"Novavax COVID-19 vaccine Covovax gets emergency use nod in Thailand","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"translate_title":"诺瓦瓦克斯医药新冠肺炎疫苗Covovax在泰获得紧急使用许可","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":0.9},"content_text":"Novavax Shares Jumped 4% in Morning Trading.Novavax COVID-19 vaccine Covovax gets emergency use nod in Thailand.Novavax  and Serum Institute of India (SII) said that the Thailand Food and Drug Administration granted emergency use authorization (EUA) to Novavax' protein-based COVID-19 vaccine NVX-CoV2373 for use in people 18 years of age and older.The vaccine is made and marketed by SII under the brand name Covovax.The companies said the approval was backed by data from clinical studies, including two phase 3 trials: PREVENT-19, which enrolled ~30K people aged 18 years and older in the U.S. and Mexico; and a trial with ~15K adult participants in the U.K.The companies noted that Covovax has received emergency use listing from the World Health Organization, and EUA in India, Indonesia, The Philippines, and Bangladesh. The vaccine is also authorized for use in adolescents aged ≥12 to <18 years in India.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9015856887,"gmtCreate":1649466294210,"gmtModify":1676534516360,"author":{"id":"3580799596568967","authorId":"3580799596568967","name":"WifeWhyWhy","avatar":"https://static.tigerbbs.com/27b090f2d194da555f7652c92f28fc6b","vip":1,"crmLevel":5,"crmLevelSwitch":1,"authorIdStr":"3580799596568967","idStr":"3580799596568967"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9015856887","repostId":1114716222,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9015803458,"gmtCreate":1649461357513,"gmtModify":1676534514514,"author":{"id":"3567323144846302","authorId":"3567323144846302","name":"Joppee","avatar":"https://static.tigerbbs.com/573bec3e2a703f6951e958c857bd2363","vip":1,"crmLevel":5,"crmLevelSwitch":0,"authorIdStr":"3567323144846302","idStr":"3567323144846302"},"htmlText":"keep on jabbing&nbsp;","listText":"keep on jabbing&nbsp;","text":"keep on jabbing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9015803458","repostId":1114716222,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9015803175,"gmtCreate":1649461305734,"gmtModify":1676534514498,"author":{"id":"3564307384077743","authorId":"3564307384077743","name":"LWayne","avatar":"https://static.itradeup.com/news/95dd7493a26e1c3e9a33a2d16eaa037b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3564307384077743","idStr":"3564307384077743"},"htmlText":"Still...","listText":"Still...","text":"Still...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9015803175","repostId":1114716222,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9015171322,"gmtCreate":1649460529333,"gmtModify":1676534514301,"author":{"id":"3565700003213382","authorId":"3565700003213382","name":"Blading23","avatar":"https://community-static.tradeup.com/news/4cd7ba668d1c755bf79285b205abdfb2","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3565700003213382","idStr":"3565700003213382"},"htmlText":"Read","listText":"Read","text":"Read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9015171322","repostId":1114716222,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9015144689,"gmtCreate":1649460152674,"gmtModify":1676534514174,"author":{"id":"4106551597750560","authorId":"4106551597750560","name":"Will.I.AM","avatar":"https://static.itradeup.com/news/0efcc50f0133a5d02433a90d6297022e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4106551597750560","idStr":"4106551597750560"},"htmlText":"Good news&nbsp;","listText":"Good news&nbsp;","text":"Good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9015144689","repostId":1114716222,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9015146976,"gmtCreate":1649459758280,"gmtModify":1676534514096,"author":{"id":"3572430244287129","authorId":"3572430244287129","name":"TANJH","avatar":"https://static.tigerbbs.com/08f0a812db3886c7089d529cb706b8fa","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3572430244287129","idStr":"3572430244287129"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9015146976","repostId":1114716222,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":513,"commentSize":22,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1114716222"}